| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DIO3 |
| Uniprot No | P55073 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-304aa |
| 氨基酸序列 | MPRQATSRLVVGEGEGSQGASGPAATMLRSLLLHSLRLCAQTASCLVLFPRFLGTAFMLWLLDFLCIRKHFLGRRRRGQPEPEVELNSEGEEVPPDDPPICVSDDNRLCTLASLKAVWHGQKLDFFKQAHEGGPAPNSEVVLPDGFQSQHILDYAQGNRPLVLNFGSCTUPPFMARMSAFQRLVTKYQRDVDFLIIYIEEAHPSDGWVTTDSPYIIPQHRSLEDRVSAARVLQQGAPGCALVLDTMANSSSSAYGAYFERLYVIQSGTIMYQGGRGPDGYQVSELRTWLERYDEQLHGARPRRV |
| 预测分子量 | 33,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DIO3重组蛋白的3篇参考文献(示例为模拟生成内容，实际文献需根据具体研究补充)：
1. **文献名称**：*Expression and Functional Characterization of Recombinant Human Type 3 Iodothyronine Deiodinase*
**作者**：Hernández A, et al.
**摘要**：研究报道了在HEK293细胞中表达重组人DIO3蛋白，并验证其酶活性。结果显示，重组DIO3可高效催化T3和T4的脱碘反应，且在缺氧条件下活性显著上调，提示其在胎儿甲状腺代谢中的关键作用。
2. **文献名称**：*Purification and Kinetic Analysis of Recombinant DIO3 in Thyroid Hormone Inactivation*
**作者**：Martínez ME, et al.
**摘要**：通过大肠杆菌系统表达并纯化重组DIO3蛋白，分析了其动力学参数。研究发现，DIO3对T3的亲和力高于T4.且其活性受硒代半胱氨酸残基调控，为靶向DIO3的病理研究提供依据。
3. **文献名称**：*DIO3 Recombinant Protein Attenuates Thyroid Hormone Signaling in Cancer Cell Models*
**作者**：Dentice M, et al.
**摘要**：利用重组DIO3处理甲状腺癌细胞，发现其通过降低细胞内活性甲状腺激素水平抑制癌细胞增殖，表明DIO3可能作为甲状腺癌治疗的潜在靶点。
(注：以上文献信息为示例性内容，实际引用需以真实发表的论文为准。)
DIO3 (iodothyronine deiodinase 3) is a selenocysteine-containing enzyme critical in regulating thyroid hormone homeostasis by inactivating active thyroid hormones (T3 and T4) through the removal of iodine atoms. It primarily catalyzes the conversion of T4 to reverse T3 (rT3) and T3 to T2. thereby modulating local and systemic thyroid hormone availability. DIO3 is particularly vital during embryonic development, tissue regeneration, and pathological conditions like cancer, where precise control of thyroid signaling is essential. Its expression is tightly spatiotemporally regulated, with high activity observed in the placenta, pregnant uterus, and developing tissues.
Recombinant DIO3 protein is engineered for research and therapeutic applications. Produced via heterologous expression systems (e.g., E. coli, mammalian cells), it retains enzymatic activity when properly folded and incorporates selenocysteine—a challenge due to the rarity of selenocysteine tRNA machinery in standard expression hosts. Advanced systems (e.g., SECIS elements, specialized vectors) are often employed to ensure correct synthesis.
Research uses include studying thyroid hormone metabolism disorders, fetal development anomalies, and diseases linked to DIO3 dysregulation (e.g., metabolic syndromes, certain cancers). In therapeutics, recombinant DIO3 holds potential for conditions requiring thyroid hormone suppression, such as hyperthyroidism or hormone-sensitive tumors. However, stability, delivery, and activity maintenance in vivo remain hurdles. Current studies focus on optimizing production and exploring its role as a biomarker or drug target, underscoring its dual significance in basic biology and translational medicine.
×
